BAGLIVO, SARA
 Distribuzione geografica
Continente #
NA - Nord America 906
AS - Asia 776
EU - Europa 553
SA - Sud America 159
AF - Africa 27
OC - Oceania 2
Totale 2.423
Nazione #
US - Stati Uniti d'America 875
SG - Singapore 379
CN - Cina 127
BR - Brasile 125
IE - Irlanda 109
IT - Italia 98
HK - Hong Kong 85
RU - Federazione Russa 78
DE - Germania 75
VN - Vietnam 58
FR - Francia 47
RO - Romania 27
KR - Corea 26
FI - Finlandia 24
IN - India 23
GB - Regno Unito 20
AR - Argentina 14
CA - Canada 14
JP - Giappone 13
BD - Bangladesh 12
PL - Polonia 12
AT - Austria 11
ES - Italia 11
MX - Messico 11
MA - Marocco 10
SE - Svezia 10
IQ - Iraq 9
NL - Olanda 8
ZA - Sudafrica 7
PK - Pakistan 6
TR - Turchia 6
VE - Venezuela 6
CH - Svizzera 5
JO - Giordania 5
EC - Ecuador 4
EG - Egitto 4
PY - Paraguay 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
GR - Grecia 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CO - Colombia 2
DZ - Algeria 2
ID - Indonesia 2
JM - Giamaica 2
LB - Libano 2
LT - Lituania 2
OM - Oman 2
PH - Filippine 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
CL - Cile 1
DO - Repubblica Dominicana 1
GA - Gabon 1
HU - Ungheria 1
IR - Iran 1
KI - Kiribati 1
LV - Lettonia 1
ME - Montenegro 1
MN - Mongolia 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
PW - Palau 1
RS - Serbia 1
SI - Slovenia 1
SO - Somalia 1
SV - El Salvador 1
TN - Tunisia 1
TW - Taiwan 1
Totale 2.423
Città #
Singapore 292
Chandler 145
Dublin 109
San Jose 107
Hong Kong 84
Ashburn 65
Beijing 37
San Mateo 35
Boardman 34
Santa Clara 34
Munich 33
Perugia 32
Bucharest 27
Seoul 26
Moscow 25
Los Angeles 23
Lauterbourg 22
Altamura 21
Lawrence 20
Medford 20
Princeton 20
Ho Chi Minh City 19
Ann Arbor 14
Helsinki 14
New York 14
Tokyo 13
Frankfurt am Main 12
Warsaw 12
Andover 11
São Paulo 11
Wilmington 11
Des Moines 9
Hanoi 9
Piscataway 9
Falkenstein 8
Nuremberg 8
Stockholm 8
The Dalles 8
Mexico City 7
Orem 7
Baghdad 6
Hefei 6
San Paolo di Civitate 6
Seattle 6
Atlanta 5
Brasília 5
Chennai 5
Haiphong 5
Houston 5
Johannesburg 5
Montreal 5
Redmond 5
Rio de Janeiro 5
Turku 5
Vienna 5
Amman 4
Arezzo 4
Brooklyn 4
Curitiba 4
Dearborn 4
Denver 4
Guangzhou 4
Lahore 4
Nanjing 4
Paris 4
Phoenix 4
Saint Petersburg 4
San Francisco 4
Amsterdam 3
Ankara 3
Bexley 3
Calgary 3
Chicago 3
Council Bluffs 3
Formia 3
Hải Dương 3
Mumbai 3
Poplar 3
Rabat 3
Rome 3
Tianjin 3
Toronto 3
Anápolis 2
Boston 2
Cairo 2
Caracas 2
City of London 2
Columbus 2
Dallas 2
Erbil 2
Faenza 2
Foligno 2
Ghaziabad 2
Governador Valadares 2
Guayaquil 2
Lappeenranta 2
Londrina 2
Manchester 2
New Delhi 2
Norfolk 2
Totale 1.624
Nome #
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 124
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 119
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 109
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 106
Non-coding RNAs in lung cancer 103
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 103
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 96
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 96
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 95
Osimertinib 94
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 94
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 90
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 88
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 88
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 84
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 83
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 80
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 75
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 74
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 74
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 72
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 70
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 69
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 68
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations 65
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 65
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 62
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs 57
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 55
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression 47
Totale 2.505
Categoria #
all - tutte 10.822
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.822


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 1 4 0
2021/2022170 1 25 1 5 4 3 1 47 2 22 24 35
2022/2023398 22 75 9 37 38 40 0 18 142 0 14 3
2023/2024158 8 10 16 6 2 2 39 1 4 5 36 29
2024/2025418 10 31 31 12 46 33 9 32 70 34 67 43
2025/20261.184 65 97 72 185 198 93 189 69 118 98 0 0
Totale 2.505